How Will Medicaid Cuts Disrupt Clinical Lab Reimbursements?

On July 4, 2025, President Donald Trump signed a sweeping domestic policy package into law, enacting $880 billion in Medicaid cuts over five years. The legislation, previously referred to as the “One Big Beautiful Bill Act,” is now expected to transform how health care—including diagnostic testing and clinical lab services—is delivered and reimbursed. 

The Congressional Budget Office (CBO) estimates that the law will result in 7.8 million Americans losing Medicaid coverage.

The law introduces fundamental changes to Medicaid eligibility, enrollment, and funding, placing new financial pressures on hospitals, clinics, and laboratories that serve low-income populations. Clinical labs that rely heavily on Medicaid reimbursements are especially vulnerable.

For clinical labs, the impacts of Medicaid restructuring fall into three main categories: reduced Medicaid enrollment, decreased federal funding, and changes to patient cost-sharing requirements.

1. Fewer Medicaid patients, more uncompensated testing

The CBO projects a significant reduction in covered lives. For labs, this means fewer reimbursed tests and more pressure to absorb costs for uninsured patients—especially in rural and underserved communities. 

In a recent article by The Dark Report, healthcare attorney Elizabeth Sullivan noted that hospitals will likely provide more charity care and pass cost-saving demands on to their reference laboratories. Labs may see greater scrutiny over send-out test pricing and reimbursement schedules.

2. Reduced federal funding to states

The law cuts federal matching funds to states, forcing many to respond by limiting Medicaid services or slashing provider payment rates. Legal expert Mike Ryan said in a recent article that states now face hard decisions: restrict covered services or lower reimbursement across the board—both scenarios that could directly reduce lab revenue. 

Additionally, advanced and specialized testing may be deprioritized in favor of lower-cost STAT and emergency-based testing, Sullivan said.

3. New cost-sharing requirements

Medicaid recipients with incomes up to 100 percent of the federal poverty level will now face copayments of up to US$35.00 per service. While primary and preventive care are exempt, cost-sharing may discourage patients from seeking non-urgent testing. Labs may face reduced test volumes as a result, while also absorbing increased administrative costs tied to billing and collections.

Additionally, the bill ends certain federal supports for states that provide health care to undocumented immigrants, which could further reduce the pool of reimbursed services.

What clinical labs should do ahead of Medicaid cuts

With the law enacted, clinical laboratories must move from preparation to implementation. 

Sullivan advised labs to focus on insurance verification protocols and stay on top of implementation deadlines—some provisions take effect as early as January 1, 2026, while others roll out through fall 2027.

State-level responses will also play a critical role, as each adjusts to the new limits on federal Medicaid support. Labs that operate across state lines should track policy shifts in each jurisdiction and align with health system partners to understand changes in coverage and reimbursement.

Clinical labs must also analyze their patient demographics and payer mix to model potential revenue impacts. Those with high Medicaid exposure may need to reevaluate service offerings or negotiate new contracts with health systems. “Labs are going to have to focus on their client base and whatever health systems and providers they are serving,” Sullivan said. “They will need to analyze what is happening in the various states in which they are located, and how that might change Medicaid coverage.”

Sullivan cautioned that while uncertainty around implementation remains, labs must not delay action or assume the impact will be minimal. “The main thing is not to lose sight of it,” she said.